PARADIGM - Patienten aktiv in der Forschung und im Dialog für eine bessere Generation von Arzneimitteln

PARADIGM’s mission was to provide a unique framework that enables structured, effective, meaningful, ethical, innovative, and sustainable patient engagement and demonstrates the ‘return on the engagement’ for all players.
The project developed much needed processes and tools for three key decision-making points: research priority setting, design of clinical trials and early dialogue. Building on advances at international level, PARADIGM integrated the needs, perspectives and expectations of all actors (including vulnerable populations) involved and also produced a set of metrics to measure the impact of patient engagement. Throughout the project, activities maximised synergies with other initiatives focusing on the patient’s voice in the life cycle of medicines, such as the Patient Focussed Medicines Development (PFMD) or the European Patient Academy on Therapeutic Innovation (EUPATI).

A free Patient Engagement Toolbox was created, centralising access to all of PARADIGM’s co-created recommendations, tools and background information to make patient engagement in medicines development easier for all, from planning to conducting to reporting and evaluation.

PARADIGM was a public-private partnership and co-led by the European Patients’ Forum (EPF) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) (Grant Agreement 777450).